{"DataElement":{"publicId":"6037645","version":"1","preferredName":"Prostate Cancer Ancillary Testing Performed Other Specify","preferredDefinition":"Text term not previously mentioned that represents the kind of ancillary testing performed for prostate cancer.","longName":"ANCL_TST_PRF_SPEC","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"6036381","version":"1","preferredName":"Prostate Carcinoma Ancillary Study Testing Performed","preferredDefinition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002_A study that is secondary to another study._A procedure for critical evaluation._Executed and carried through to completion.","longName":"2744055v1.0:6036379v1.0","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"2744055","version":"1","preferredName":"Prostate Carcinoma","preferredDefinition":"Prostate carcinoma is one of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002","longName":"C4863","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Carcinoma","conceptCode":"C4863","definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B8AEEC8-FDF2-03F8-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-04-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-04-23","modifiedBy":"ONEDATA","dateModified":"2008-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6036379","version":"1","preferredName":"Ancillary Study Testing Performed","preferredDefinition":"A study that is secondary to another study.:A procedure for critical evaluation.:Executed and carried through to completion.","longName":"C16041:C15336:C38000","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ancillary Study","conceptCode":"C16041","definition":"A study that is secondary to another study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Testing","conceptCode":"C15336","definition":"A procedure for critical evaluation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Performed","conceptCode":"C38000","definition":"Executed and carried through to completion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F89E81C-E9CB-1F20-E053-F662850A1F8A","latestVersionIndicator":"Yes","beginDate":"2017-12-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-12-04","modifiedBy":"ONEDATA","dateModified":"2017-12-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435018","version":"1","preferredName":"Clinical or Research Activity","preferredDefinition":"Any specific activity undertaken during the course of a clinical study or research protocol.","longName":"C16203","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741AE5B-831E-25C7-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F89E81C-E9DC-1F20-E053-F662850A1F8A","latestVersionIndicator":"Yes","beginDate":"2017-12-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-12-04","modifiedBy":"COOPERM","dateModified":"2017-12-06","changeDescription":"Created for Dr. Turkbey P173316 request 11.21.17 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2666713","version":"2","preferredName":"Other Specify","preferredDefinition":"Different than the one(s) previously specified or mentioned._Be specific about something; define clearly.","longName":"OTH_SPEC","context":"NCI Standards","contextVersion":"1","type":"Non-enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2208051","version":"1","preferredName":"Other Specify","preferredDefinition":"Not otherwise specified.:Specify; be specific about something; define clearly.","longName":"C17649:C25685","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Specify","conceptCode":"C25685","definition":"Be specific about something; define clearly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-3B5E-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCI CRF Standards","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"132D4785-528E-5337-E050-BB89AD433CA8","latestVersionIndicator":"Yes","beginDate":"2015-04-07","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2015-04-07","modifiedBy":"HARTLEYG","dateModified":"2018-06-06","changeDescription":"7/19/17 jk transferred context and added registration status, CSI per Round 5 finalization task. 4/28/15 released. jc  4/7/15 VD versioned per COG WG: inc to 100 char, remove min limit, chg concept domain to assessment result. jc 1/25/13 added ACRIN Old caBIG CSI.  3/21/12 - changed origin from IVI to ACRIN.  3/5/08 - released for UoWASH FES CRF.   7/23/07-created for ACRIN PET CDEs","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Other, specify","type":"Preferred Question Text","description":"Other, specify","url":null,"context":"CCR"}],"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F9F85E1-1F5E-76DE-E053-F662850A148B","latestVersionIndicator":"Yes","beginDate":"2017-12-05","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-12-05","modifiedBy":"COOPERM","dateModified":"2017-12-06","changeDescription":"Created for Dr. Turkbey P173316 request 12.05.17 ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}